Navigation Links
Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
Date:3/5/2009

"Vascular access complications represent a significant healthcare problem, and we were impressed by the market opportunity for PRT-201 and with the quality of Proteon's team," said Dr. Steven St. Peter, Managing Director of MPM Capital. "We are pleased to be a part of this successful financing structure, and I look forward to working closely with Proteon."

About PRT-201

PRT-201 is a recombinant human elastase that is being studied for its ability to improve arteriovenous fistula (AVF) surgery outcomes in patients requiring chronic hemodialysis. PRT-201 has been shown to cause dilation of segments of arteries and veins following topical intraoperative application in animals. Vessel dilation and increased blood flow through the fistula may decrease AVF maturation failure rates. Improved maturation rates may lead to fewer corrective surgical procedures, hospitalizations, lower costs, and less suffering for dialysis patients. PRT-201 also will be studied for its ability to prolong the patency of arteriovenous grafts (AVGs).

About Proteon Therapeutics

Proteon Therapeutics, Inc., is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases. The company is headquartered in Waltham, Mass., and has research facilities in Kansas City, Mo. For additional information, please visit www.proteontherapeutics.com.

About MPM Capital

MPM Capital is one of the world's largest life science-dedicated venture investors. With committed capital under management in excess of $2.4 billion, MPM Capital is uniquely structured to invest globally in healthcare innovation.


'/>"/>
SOURCE Proteon Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008
2. National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc.
3. Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins
4. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
5. Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007
6. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
7. Pharmexa and Affitech to Combine Operations to Create a New Antibody Therapeutics Company
8. ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
9. Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer
10. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
11. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 22, 2014 Research and Markets ... Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction ... to their offering. The global molecular ... 2013, and is expected to grow at a CAGR ... biology enzymes, kits, & reagents find applications in a ...
(Date:8/21/2014)... , Aug. 21, 2014  BioSpecifics Technologies ... company developing first in class collagenase-based products marketed ... CCH) in the U.S. and XIAPEX ® ... results from a randomized, double-blind Phase 2a study ... or edematous fibrosclerotic panniculopathy. The results showed that ...
(Date:8/21/2014)... , August 21, 2014 ... http://www.researchandmarkets.com/research/3zh3q8/global_hormone ) has announced the addition of ...  report to their offering.       ... as hormone therapy, is a means of ... produced by the body. This type of ...
(Date:8/21/2014)... , Aug. 21, 2014 Mathematic studies at the ... University , and funded by the Jeffrey Epstein VI ... tumors can be visually identified for elimination. These aggressive cells ... study, which shows a topological map of what to look ... cancer research, for while tumor cells can be extracted from ...
Breaking Biology Technology:Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 2Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2
... GeoPharma, Inc. (Nasdaq:,GORX) (the "Company") announced today in an ... audience as possible it has placed both of the ... at, http://www.GeoPharmainc.com under the "Analyst Coverage" tab in ... publicly several times in,the next few months., In ...
... Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that ... is scheduled to present,a company overview at the BIO ... February 11 at 11:45 a.m. EST., To access ... on to http://www.rigel.com . Please connect to Rigel,s ...
... Feb. 6 Cell Therapeutics, Inc. (CTI),(Nasdaq: CTIC ; MTAX) management will ... at 1:15 PM in the West Foyer,of the Waldorf-Astoria Hotel., The presentation ... The webcast can be accessed at, http://www.cticseattle.com ., , ... BIO CEO & Investor Conference ...
Cached Biology Technology:Recent Research Reports and Near-Term Corporate Events 2Recent Research Reports and Near-Term Corporate Events 3
(Date:8/22/2014)... In 2015, American consumers will finally be able to ... Although touted as zero-emissions vehicles, most of the cars ... fossil fuel that contributes to global warming. , Now ... device that uses an ordinary AAA battery to produce ... electric current through two electrodes that split liquid water ...
(Date:8/21/2014)... A new study of American singles found that ... the highest orgasm rates. On average, men experience ... sexual orientation making little difference. For women, however, ... experience orgasm 62.9 percent of the time during ... pattern varies with women,s sexual orientation, with lesbian ...
(Date:8/21/2014)... skin fungus linked to dandruff, eczema and other itchy, ... even further global reachesincluding Hawaiian coral reefs and the ... , A review in the scientific journal PLOS ... the fungi of the genus Malassezia in ... datasets from around the world. , University of Hawai,i ...
Breaking Biology News(10 mins):Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 4From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2
... entities conducting research in synthetic biology worldwide grew significantly ... of an interactive map produced by the Synthetic Biology ... The map is available online at http://www.synbioproject.org/map . ... the design and construction of new biological parts and ...
... Centers for Disease Control, about one in six Americans gets ... of raw oysters in the U.S. are estimated to cost ... of health risk from eating raw oysters, Texas A&M University ... scientist Dr. Suresh Pillai and a team of researchers from ...
... 2013 Signal Hill, CA Bowman Design Group, an ... exhibits, and event marketing, is the first and only ... certification from FAMAB, the German exhibition and events industry ... established that the company met or exceeded goals set ...
Cached Biology News:Synthetic biology research community grows significantly 2Electron-beam pasteurization of raw oysters may reduce viral food poisoning 2Electron-beam pasteurization of raw oysters may reduce viral food poisoning 3Bowman Design Group is first US company awarded German FAMAB 'Sustainable Company' certification 2
... Time- and temperature-controlled microwave oven ... and Antigen Retrieval of formalin-fixed, ... ease of use, high throughput ... high performance. When used in ...
... reagents and supplies, for 10 chips, ... to perform protein analysis with 10 ... system. Supplied are 3 x 520 ... stain, 60 microliters Pro260 ladder (10-260 ...
...
... submicron range are part of your production ... of particle size is important to you. ... detect the component populations in your sample ... Analyzer uses Photon Correlation Spectroscopy (PCS) , ...
Biology Products: